- Home
- SGP vs PHAR Comparison
SGP vs PHAR Comparison
Compare SGP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | PHAR |
|---|---|---|
| Founded | 2019 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SGP | PHAR |
|---|---|---|
| Price | $24.53 | $17.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $45.00 | $38.33 |
| AVG Volume (30 Days) | ★ 100.3K | 13.3K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.15 | $8.05 |
| 52 Week High | $30.56 | $21.34 |
Technical Indicators
Market Signals| Indicator | SGP | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 63.77 |
| Support Level | $20.72 | $16.90 |
| Resistance Level | $28.17 | $19.05 |
| Average True Range (ATR) | 2.10 | 0.62 |
| MACD | 0.24 | 0.18 |
| Stochastic Oscillator | 72.70 | 82.39 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.